Skip to content
RushPR News – Lifestyle
Author:
Indivior Pharmaceuticals Inc.
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
March 31, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
March 17, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
March 12, 2026
←
Previous Page
1
2